Form 4: Nektar R&D Chief's Equity Vesting & Tax Sale

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, reported the vesting of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, reported changes in his beneficial ownership of company securities.
• On November 21, 2025, Mr. Zalevsky acquired 2,666 shares of Common Stock due to the vesting of restricted stock units (RSUs).
• These RSUs were granted on December 18, 2020, under the Issuer's Amended and Restated 2017 Performance Incentive Plan and met both performance-based and time-based vesting requirements.
• The Compensation Committee determined on November 20, 2025, that the performance-based vesting requirement for these RSUs was satisfied.
• On November 25, 2025, Mr. Zalevsky sold 1,157 shares of Common Stock at a weighted average price of $54.28 per share.
• This sale was executed to cover required tax withholding obligations in connection with the RSU vesting and was not a discretionary trade.
• On November 21, 2025, Mr. Zalevsky also acquired 4,766 stock options due to vesting.
• These stock options were granted on December 18, 2020, under the 2017 Plan and also met both performance-based and time-based vesting requirements, as determined by the Compensation Committee on November 20, 2025.

Sentiment

Score: 7

Explanation: The vesting of equity compensation is a positive event for the executive, indicating the achievement of performance targets. The subsequent sale of shares for tax purposes is a routine, non-discretionary event and does not reflect negative sentiment towards the company or its prospects.

Positives

• The vesting of restricted stock units and stock options indicates that performance-based vesting requirements were satisfied, suggesting the executive met specific company goals.
• The acquisition of 2,666 shares of Common Stock and 4,766 stock options increases the Chief R&D Officer's equity stake in the company (net of tax sales), aligning his interests with shareholders.

Negatives

• The sale of 1,157 shares of Common Stock, even for tax purposes, reduces the direct beneficial ownership of the Chief R&D Officer.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Organization and Compensation Committee of the Board of Directors determined on November 20, 2025, that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025.
• The Organization and Compensation Committee of the Board of Directors determined on November 20, 2025, that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025.

Industry Context

This Form 4 filing details a routine insider compensation event, specifically the vesting of equity awards and a subsequent tax-related sale. It does not provide information directly related to broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The vesting of RSUs results in a minor increase in outstanding shares, but this is a routine part of executive compensation plans. The transaction itself is unlikely to have a significant impact on share price.
• Executive (Jonathan Zalevsky): The vesting of RSUs and stock options increases his personal wealth and aligns his long-term interests with the company's performance, despite the partial sale for tax purposes.

Key Dates

Recommendation

This Form 4 details a routine vesting of equity compensation and a subsequent non-discretionary sale of shares to cover tax obligations by a Chief R&D Officer. Such transactions are pre-scheduled and do not reflect a discretionary investment decision or new material information about the company's operational performance or future prospects. Therefore, it provides no basis for a change in investment recommendation.

Keywords

Nektar Therapeutics, NKTR, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Jonathan Zalevsky, Chief R&D Officer, Vesting